PEPIDH1M

Drug Profile

PEPIDH1M

Alternative Names: Cancer vaccine - Annias Immunotherapeutics; Cytomegalovirus vaccine - Annias Immunotherapeutics; Dendritic cell vaccine - Annias Immunotherapeutics; PEP CMV

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator Duke University
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma

Most Recent Events

  • 10 Aug 2016 Annias Immunotherapeutics, Duke University Medical Center, National Cancer Institute and National Institutes of Health plan the phase I PERFORMANCE trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA (Intradermal) (NCT02864368)
  • 10 Apr 2015 Duke University plans a phase I trial for Glioblastoma (Combination therapy, Recurrent, Early-stage disease) in USA (NCT02193347)
  • 13 Mar 2015 PEPIDH1M licensed to Annias Immunotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top